<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02083354</url>
  </required_header>
  <id_info>
    <org_study_id>200104</org_study_id>
    <secondary_id>CDRB436B2205</secondary_id>
    <nct_id>NCT02083354</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma</brief_title>
  <official_title>An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multi-center, Phase II study to evaluate dabrafenib and&#xD;
      trametinib combination therapy in subjects with BRAF V600 mutation-positive, unresectable or&#xD;
      metastatic Acral lentiginous or cutaneous melanoma. This study will evaluate the objective&#xD;
      response rate (ORR), progression free survival (PFS), duration of response, overall survival&#xD;
      (OS), safety and efficacy, to assess steady state (all subjects) exposure to dabrafenib,&#xD;
      dabrafenib metabolites, and trametinib and characterize the population pharmacokinetics (PK)&#xD;
      and pharmacodynamics (PD) of dabrafenib and trametinib. Subjects will be enrolled and will&#xD;
      receive dabrafenib 150 milligram (mg) orally twice daily and trametinib 2 mg orally once&#xD;
      daily. Treatment will continue until disease progression, death, unacceptable toxicity, or&#xD;
      withdrawal of consent, or study closure. After treatment discontinuation, subjects will be&#xD;
      followed for survival and disease progression as applicable.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2014</start_date>
  <completion_date type="Actual">April 19, 2021</completion_date>
  <primary_completion_date type="Actual">February 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>To determine ORR of dabrafenib in combination with trametinib in subjects with BRAF V600 mutation-positive, unresectable or metastatic melanoma. ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 and as assessed by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Antitumor Activity by Assessing the Progression-free Survival (PFS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Antitumor Activity by Assessing the Duration of Response</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Duration of response is defined as the time from first documented evidence of CR or PR until the earliest date of documented radiological progression or death due to any cause among subjects who achieved a confirmed CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Antitumor Activity by Assessing the Overall Survival (OS)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>OS defined as the interval from first dose of study treatment to the date of death, irrespective of the cause of death; subjects still alive will be censored at the date of the last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess Exposures to Dabrafenib, Dabrafenib Metabolites, and Trametinib, and Characterize the Population Pharmacokinetics of Dabrafenib and Trametinib</measure>
    <time_frame>Pre-dose (within 30 minutes prior to dosing) and 1, 2, 4, 6, and 8 hours after dosing on Day 15. For subjects in China: Pre-dose (within 30 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours after dosing on Day 1 and Day 15</time_frame>
    <description>PK parameters will include maximum peak concentration (Cmax), Time to Cmax (tmax), Predose concentration (Ctau), Area under the concentration-time curve (AUC) from time 0 to last time of quantifiable concentration (AUC [0-t]), and from time 0 to 8 hours of quantifiable concentration (AUC[0-8]); AUC from time 0 to 12 hours of quantifiable concentration (AUC[0-12]) (dabrafenib and metabolites only), AUC (0-24) (trametinib only) and the metabolite to dabrafenib ratio of AUC(0-t). Population PK parameters will include, apparent clearance following oral dosing (CL/F), volume of distribution (V/F), and absorption rate constant (Ka) for dabrafenib and trametinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Dabrafenib and Trametinib as Assessed by Physical Examinations</measure>
    <time_frame>Screening, every 4 weeks and at treatment discontinuation (approximately 1 year but can be up to 5 years)</time_frame>
    <description>Complete physical examination will include assessments of eyes, neurological and cardiovascular systems, lungs, abdomen, and any other areas with signs and symptoms of disease, and of the head, neck, ears, nose, mouth, throat, thyroid, lymph nodes, extremities, and a full skin exam to assess cutaneous malignancies and proliferative skin diseases. Also, thorough genitourinary (pelvic) and rectal examinations to assess secondary malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Dabrafenib and Trametinib as Assessed by Vital Signs</measure>
    <time_frame>Screening, every 4 weeks and at treatment discontinuation (approximately 1 year but can be up to 5 years)</time_frame>
    <description>Vital sign measurements will include systolic and diastolic blood pressure, body temperature, pulse rate, body weight, and height (only at Screening)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Dabrafenib and Trametinib as Assessed by 12-lead Electrocardiograms (ECG), Echocardiogram (ECHO)</measure>
    <time_frame>ECG Screening, Day 15, Week 4, 8 and 12, every 12 weeks after Week 12 and treatment Discontinuation(approximately 1 year but can be up to 5 years). ECHO Screening, Week 4 and every 12 weeks</time_frame>
    <description>Clinical assessments including 12-lead (ECG, ECHO will be done to assess cardiac safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Dabrafenib and Trametinib as Assessed by Eye Examinations</measure>
    <time_frame>Screening and Week 4 and as clinically warranted</time_frame>
    <description>Safety as measured by clinical assessments including eye exams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Dabrafenib and Trametinib by Laboratory Assessments</measure>
    <time_frame>Screening, every 4 weeks and at treatment Discontinuation (approximately 1 year but can be up to 5 years)</time_frame>
    <description>Laboratory assessments will include clinical chemistry and hematology parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Dabrafenib and Trametinib as Assessed Adverse Events (AEs)</measure>
    <time_frame>From the first dose of study treatment until 30 days after discontinuation of study treatment (approximately 1 year but can be up to 5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose. Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent, which includes compliance with the requirements and&#xD;
             restrictions listed in the consent form.&#xD;
&#xD;
          -  &gt;=18 years of age.&#xD;
&#xD;
          -  Histologically confirmed acral lentiginous or cutaneous melanoma that is either Stage&#xD;
             IIIC (unresectable) or Stage IV (metastatic), and BRAF V600 mutation-positive. The&#xD;
             test was to have been conducted at a designated central laboratory.&#xD;
&#xD;
          -  Measurable disease (i.e., present with at least one measurable lesion) by RECIST&#xD;
             version1.1.&#xD;
&#xD;
          -  Performance status score of 0 or 1 according to the Eastern Cooperative Oncology Group&#xD;
             (ECOG) scale.&#xD;
&#xD;
          -  All prior anti-cancer treatment-related toxicities (except alopecia and laboratory&#xD;
             values) must be &lt;=Grade 1 according to the Common Terminology Criteria for Adverse&#xD;
             Events version 4 (CTCAE version 4.0) at the time of enrolment.&#xD;
&#xD;
          -  Able to swallow and retain oral medication and must not have had any clinically&#xD;
             significant gastrointestinal abnormalities that may alter absorption such as&#xD;
             malabsorption syndrome or major resection of the stomach or bowels.&#xD;
&#xD;
          -  Women of child-bearing potential must have had a negative serum pregnancy test within&#xD;
             14 days of first dose of study treatment and agree to use effective contraception,&#xD;
             from 14 days prior to enrolment, throughout the treatment period and for 4 months&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
          -  Adequate baseline organ function as defined below: Absolute Neutrophil Count:&gt;= 1.2 Ã—&#xD;
             10^9/liter (L); Hemoglobin: &gt;=9 grams (g)/deciliter (dL); Platelet count: &gt;=100 x&#xD;
             10^9/L; Prothrombin Time/International Normalized Ratio (INR) (Subjects receiving&#xD;
             anticoagulation treatment may be allowed to participate with INR established within&#xD;
             the therapeutic range prior to enrolment) and Partial Thromboplastin Time: &lt;=1.5 x&#xD;
             Upper Limit of Normal (ULN); Albumin: &gt;=2.5 g/dL; Total bilirubin: &lt;=1.5 x ULN;&#xD;
             Aspartate aminotransferase and Alanine aminotransferase: &lt;=2.5 x ULN; Calculated&#xD;
             creatinine clearance (Calculate creatinine clearance using standard Cockcroft-Gault&#xD;
             formula): &gt;=50 milliliter (mL)/ minute (min); Left Ventricular Ejection Fraction&#xD;
             (LVEF) (ECHO scans must be used throughout the study) : &gt;= Lower limit of normal (LLN)&#xD;
             by ECHO.&#xD;
&#xD;
          -  Subjects with East Asian origin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary mucosal or ocular melanoma.&#xD;
&#xD;
          -  Prior treatment with a BRAF inhibitor (including but not limited to dabrafenib,&#xD;
             vemurafenib, LGX818, and XL281/BMS-908662) or a MEK inhibitor (including but not&#xD;
             limited to trametinib, AZD6244, and RDEA119).&#xD;
&#xD;
          -  Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity,&#xD;
             biologic anti-cancer therapy, or immuno anti-cancer therapy within 21 days prior to&#xD;
             enrolment /or daily or weekly chemotherapy without the potential for delayed toxicity&#xD;
             within 14 days prior to enrolment. (Note: Ipilimumab, pembrolizumab and nivolumab&#xD;
             treatment must ended at least 8 weeks prior to enrollment).&#xD;
&#xD;
          -  Taken an investigational drug within 28 days or 5 half-lives (minimum 14 days),&#xD;
             whichever is shorter, prior to enrolment. (Note: in case ipilimuamb, pembrolizmab and&#xD;
             nivolumab are investigational drug in the regions and countries, and in case of PD-L1&#xD;
             antibody, these investigational treatment must have ended at least 8 weeks prior to&#xD;
             enrollment ).&#xD;
&#xD;
          -  Current use of a prohibited medication.&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to the study treatments, their excipients, and/or dimethyl&#xD;
             sulfoxide (DMSO).&#xD;
&#xD;
          -  A history of Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects&#xD;
             with laboratory evidence of cleared HBV and/or HCV will be permitted).&#xD;
&#xD;
          -  Leptomeningeal or brain metastases or metastases causing spinal cord compression that&#xD;
             were: symptomatic or untreated or not stable for 3 months (must be documented by&#xD;
             imaging) or requiring corticosteroids. Subjects that were on a stable dose of&#xD;
             corticosteroids &gt;1 month or on replacement dose only, or have been off of&#xD;
             corticosteroids for at least 2 weeks can be enrolled with approval of the medical&#xD;
             monitor. Subjects must also have been off of enzyme-inducing anticonvulsants for &gt;4&#xD;
             weeks.&#xD;
&#xD;
          -  History of malignancy other than disease under study within 3 years of study enrolment&#xD;
             with exceptions of subjects with a history of completely resected non-melanoma skin&#xD;
             cancer, or subjects with indolent second malignancies were eligible only after the&#xD;
             approval of the sponsor's medical monitor.&#xD;
&#xD;
          -  History of malignancy with confirmed activating RAS mutation at any time. Note:&#xD;
             Prospective RAS testing was not required. However, if the results of previous RAS&#xD;
             testing were known, they must have been used in assessing eligibility&#xD;
&#xD;
          -  Any serious or unstable pre-existing medical conditions (aside from malignancy&#xD;
             exceptions specified above), psychiatric disorders, or other conditions that could&#xD;
             have interfered with the subject's safety, obtaining informed consent, or compliance&#xD;
             with study procedures.&#xD;
&#xD;
          -  A history or evidence of cardiovascular risk including any of the following: Current&#xD;
             LVEF &lt; Institutional LLN; A QTc interval corrected for heart rate &gt;=480 millisecond&#xD;
             (msec) (using Bazett's formula); A history or evidence of current clinically&#xD;
             significant uncontrolled arrhythmias. Clarification: Subjects with atrial fibrillation&#xD;
             controlled for &gt;30 days prior to dosing are eligible; A history of acute coronary&#xD;
             syndromes (including myocardial infarction or unstable angina), coronary angioplasty,&#xD;
             or stenting within 6 months prior to randomization; A history or evidence of current&#xD;
             &gt;=Class II congestive heart failure as defined by the New York Heart Association&#xD;
             (NYHA) guidelines; Patients with intra-cardiac defibrillators; Treatment refractory&#xD;
             hypertension defined as a blood pressure of systolic &gt;140 millimeters of mercury&#xD;
             (mmHg) and/or diastolic &gt;90 mmHg which cannot be controlled by anti-hypertensive&#xD;
             therapy; Known cardiac metastases; Abnormal cardiac valve morphology (&gt;=grade 2)&#xD;
             documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild&#xD;
             regurgitation/stenosis] can be entered on study). Subjects with moderate valvular&#xD;
             thickening should not have been entered in study.&#xD;
&#xD;
          -  Uncorrectable electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia,&#xD;
             hypocalcaemia determined by blood chemistry), long QT syndrome or taking medicinal&#xD;
             products known to prolong the QT interval.&#xD;
&#xD;
          -  A history or current evidence of retinal vein occlusion (RVO) .&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  History of or current diagnosis of interstitial lung disease or pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650106</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuen Mun</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10320</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <results_first_submitted>February 15, 2021</results_first_submitted>
  <results_first_submitted_qc>March 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 17, 2021</results_first_posted>
  <disposition_first_submitted>October 10, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 15, 2019</disposition_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>dabrafenib</keyword>
  <keyword>trametinib</keyword>
  <keyword>malignant skin cancer</keyword>
  <keyword>skin cancer</keyword>
  <keyword>BRAF V600 Mutation-Positive Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02083354/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02083354/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>77 participants were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>All subjects received the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone was to be administered approximately 12 hours after the morning dose. Subjects were to continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>All subjects received the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone was to be administered approximately 12 hours after the morning dose. Subjects were to continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.6" spread="13.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>To determine ORR of dabrafenib in combination with trametinib in subjects with BRAF V600 mutation-positive, unresectable or metastatic melanoma. ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 and as assessed by the investigator.</description>
        <time_frame>Up to 35 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>All subjects received the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone was to be administered approximately 12 hours after the morning dose. Subjects were to continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>To determine ORR of dabrafenib in combination with trametinib in subjects with BRAF V600 mutation-positive, unresectable or metastatic melanoma. ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 and as assessed by the investigator.</description>
          <population>Full Analysis Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="49.2" upper_limit="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Antitumor Activity by Assessing the Progression-free Survival (PFS)</title>
        <description>PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause</description>
        <time_frame>Up to 36 months</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Antitumor Activity by Assessing the Duration of Response</title>
        <description>Duration of response is defined as the time from first documented evidence of CR or PR until the earliest date of documented radiological progression or death due to any cause among subjects who achieved a confirmed CR or PR</description>
        <time_frame>Up to 36 months</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Antitumor Activity by Assessing the Overall Survival (OS)</title>
        <description>OS defined as the interval from first dose of study treatment to the date of death, irrespective of the cause of death; subjects still alive will be censored at the date of the last contact</description>
        <time_frame>Approximately 5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess Exposures to Dabrafenib, Dabrafenib Metabolites, and Trametinib, and Characterize the Population Pharmacokinetics of Dabrafenib and Trametinib</title>
        <description>PK parameters will include maximum peak concentration (Cmax), Time to Cmax (tmax), Predose concentration (Ctau), Area under the concentration-time curve (AUC) from time 0 to last time of quantifiable concentration (AUC [0-t]), and from time 0 to 8 hours of quantifiable concentration (AUC[0-8]); AUC from time 0 to 12 hours of quantifiable concentration (AUC[0-12]) (dabrafenib and metabolites only), AUC (0-24) (trametinib only) and the metabolite to dabrafenib ratio of AUC(0-t). Population PK parameters will include, apparent clearance following oral dosing (CL/F), volume of distribution (V/F), and absorption rate constant (Ka) for dabrafenib and trametinib</description>
        <time_frame>Pre-dose (within 30 minutes prior to dosing) and 1, 2, 4, 6, and 8 hours after dosing on Day 15. For subjects in China: Pre-dose (within 30 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours after dosing on Day 1 and Day 15</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Dabrafenib and Trametinib as Assessed by Physical Examinations</title>
        <description>Complete physical examination will include assessments of eyes, neurological and cardiovascular systems, lungs, abdomen, and any other areas with signs and symptoms of disease, and of the head, neck, ears, nose, mouth, throat, thyroid, lymph nodes, extremities, and a full skin exam to assess cutaneous malignancies and proliferative skin diseases. Also, thorough genitourinary (pelvic) and rectal examinations to assess secondary malignancies</description>
        <time_frame>Screening, every 4 weeks and at treatment discontinuation (approximately 1 year but can be up to 5 years)</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Dabrafenib and Trametinib as Assessed by Vital Signs</title>
        <description>Vital sign measurements will include systolic and diastolic blood pressure, body temperature, pulse rate, body weight, and height (only at Screening)</description>
        <time_frame>Screening, every 4 weeks and at treatment discontinuation (approximately 1 year but can be up to 5 years)</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Dabrafenib and Trametinib as Assessed by 12-lead Electrocardiograms (ECG), Echocardiogram (ECHO)</title>
        <description>Clinical assessments including 12-lead (ECG, ECHO will be done to assess cardiac safety</description>
        <time_frame>ECG Screening, Day 15, Week 4, 8 and 12, every 12 weeks after Week 12 and treatment Discontinuation(approximately 1 year but can be up to 5 years). ECHO Screening, Week 4 and every 12 weeks</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Dabrafenib and Trametinib as Assessed by Eye Examinations</title>
        <description>Safety as measured by clinical assessments including eye exams</description>
        <time_frame>Screening and Week 4 and as clinically warranted</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Dabrafenib and Trametinib by Laboratory Assessments</title>
        <description>Laboratory assessments will include clinical chemistry and hematology parameters</description>
        <time_frame>Screening, every 4 weeks and at treatment Discontinuation (approximately 1 year but can be up to 5 years)</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Dabrafenib and Trametinib as Assessed Adverse Events (AEs)</title>
        <time_frame>From the first dose of study treatment until 30 days after discontinuation of study treatment (approximately 1 year but can be up to 5 years)</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 35 months (for both dabrafenib and also trametinib).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>All Patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (23.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+ 1 862 778 8300</phone>
      <email>Novartis.email@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

